Cargando…
Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol
Anti-TNFα therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFα agent, a nanomolecule comprising a humanized Fab’ antibody fragment against TNFα with a polyethylene glycol tail, is shortly to com...
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673817/ https://www.ncbi.nlm.nih.gov/pubmed/17722505 |
| Sumario: | Anti-TNFα therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFα agent, a nanomolecule comprising a humanized Fab’ antibody fragment against TNFα with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place. |
|---|